Give it a thorough read when you have time; it's a well thought-out study. If you read the details, you might see that the results actually appear good. I find the results promising.
I think their next trial (which is currently recruiting patients)
might show better results. This study's results show the vaccine might need longer duration of use to show a better efficacy rate. A trial with a larger population, longer treatment duration, endoscopic and histological evaluation; in addition to what they have looked for in this trial might show a more solid effect. This published study may not be really optimally designed to see the treatment's effects in its full capacity.
Apart from that, the study is well designed in my opinion, and judging from their article, they likely designed an even better study in terms of evaluating the efficacy for their currently recruiting Crohn's trial
study article said...https://www.frontiersin.org/articles/10.3389/fmed.2019.00170/full
The data from this trial will inform the design of larger definitive Phase II trials, which will include evaluation of endoscopic and histological endpoints, assessment of the impact of prior TNFα inhibitor exposure on QBECO response, evaluation of patients over a longer treatment period, microbiome assessment, and confirmation of the genetic and immune biomarker findings.
I don't keep my hopes too high, or support fanatically any future possible treatment option; but it's good to keep an eye on these kinds of studies that have a different focus than immunosuppression. Who knows, maybe we will get a cure (or a very good drug [low toxicity, high efficacy]) one day.